Prilosec OTC Patent Extension Request “Compels” Name Change – Mylan
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca's efforts to extend a patent for Prilosec OTC bolster the case for mandating a name change for the nonprescription product, Mylan says in Oct. 29 comments to FDA
You may also be interested in...
OTC Prilosec Name Derivative Has Precedent In Other Rx Heartburn Switches
FDA has set multiple precedents of switching Rx heartburn remedies over-the-counter while permitting the same trade name for both versions, and should not force a name change for Prilosec OTC, Procter & Gamble says in recent comments to FDA
OTC Prilosec Name Derivative Has Precedent In Other Rx Heartburn Switches
FDA has set multiple precedents of switching Rx heartburn remedies over-the-counter while permitting the same trade name for both versions, and should not force a name change for Prilosec OTC, Procter & Gamble says in recent comments to FDA
OTC Prilosec Name Derivative Has Precedent In Other Rx Heartburn Switches
FDA has set multiple precedents of switching Rx heartburn remedies over-the-counter while permitting the same trade name for both versions, and should not force a name change for Prilosec OTC, Procter & Gamble says in recent comments to FDA